CervoMed Secures $10 Million to Advance Brain Disease Pipeline
BOSTON, June 18, 2026 CervoMed Inc., a clinical-stage biotechnology company focused on developing therapies for age-related neurological disorders, has...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOSTON, June 18, 2026 CervoMed Inc., a clinical-stage biotechnology company focused on developing therapies for age-related neurological disorders, has...
VALBY, Denmark and AMSTERDAM, Netherlands, June 3, 2026 Lundbeck and Cradle have announced a strategic partnership aimed at transforming...
